Cardiovascular Systems

Cardiovascular Systems is a medical device company. CSI is focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Our primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications it presents for the millions who suffer from peripheral arterial disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes.

Company Growth (employees)
Type
Public
HQ
Saint Paul, US
Size (employees)
581 (est)
Website
csi360.com
Cardiovascular Systems is headquartered in Saint Paul, US

Key People at Cardiovascular Systems

Scott R. Ward

Scott R. Ward

Chairman, President & CEO
Laurence L. Betterley

Laurence L. Betterley

CFO
Kevin J. Kenny

Kevin J. Kenny

Chief Operating Officer
James E. Flaherty

James E. Flaherty

CAO

Cardiovascular Systems Office Locations

Cardiovascular Systems has offices in Saint Paul and Rochester
Saint Paul, US (HQ)
1225 Old Hwy 8 NW
Saint Paul, US
651 Campus Drive
Rochester, US
651 Campus Drive

Cardiovascular Systems Data and Metrics

Cardiovascular Systems Financial Metrics

Cardiovascular Systems's revenue was reported to be $52.1 m in Q3, 2017
USD

Revenue (Q3, 2017)

52.1 m

Gross profit (Q3, 2017)

41 m

Gross profit margin (Q3, 2017), %

79%

Net income (Q3, 2017)

(2.6 m)

EBIT (Q3, 2017)

(1.8 m)

Market capitalization (22-Aug-2017)

973.7 m

Cash (31-Mar-2017)

103.1 m
Cardiovascular Systems's current market capitalization is $973.7 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

136.6 m181.5 m178.2 m

Revenue growth, %

33%(2%)

Cost of goods sold

31 m39.5 m35.4 m

Gross profit

105.6 m142 m142.8 m

Gross profit Margin, %

77%78%80%

R&D expense

25.9 m

General and administrative expense

162.5 m

Operating expense total

188.5 m

EBIT

(33.5 m)(32.6 m)(56.1 m)

EBIT margin, %

(25%)(18%)(31%)

Net Income

(35.3 m)(32.8 m)(56 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

41.4 m44.7 m47 m43.9 m41.4 m44.5 m49.8 m50 m52.1 m

Cost of goods sold

8.9 m9.3 m10.4 m8.8 m8.1 m8.7 m9.5 m9.2 m11.1 m

Gross profit

32.5 m35.4 m36.6 m35.1 m33.3 m35.7 m40.3 m40.9 m41 m

Gross profit Margin, %

79%79%78%80%81%80%81%82%79%

R&D expense

7.2 m8.1 m7.8 m6.9 m7.2 m5.7 m5.3 m5.8 m5.4 m

General and administrative expense

33.5 m32.6 m39.4 m41.4 m41.3 m42.3 m36.9 m34 m37.3 m

Operating expense total

40.7 m40.6 m47.1 m48.3 m48.5 m48.1 m42.2 m39.8 m42.8 m

EBIT

(8.2 m)(5.3 m)(10.5 m)(13.2 m)(15.1 m)(22.7 m)(1.9 m)1.1 m(1.8 m)

EBIT margin, %

(20%)(12%)(22%)(30%)(37%)(51%)(4%)2%(3%)

Pre tax profit

(1.8 m)1.1 m(1.7 m)

Income tax expense

24 k24 k18 k

Net Income

(8.2 m)(13.5 m)(24.2 m)(13.3 m)(28.4 m)(51.1 m)(1.9 m)(815 k)(2.6 m)
USDFY, 2014FY, 2015FY, 2016

Cash

126.6 m83.8 m60.6 m

Accounts Receivable

21.4 m30.8 m23.1 m

Inventories

12.9 m14 m17.4 m

Current Assets

162.7 m133.9 m104.9 m

PP&E

15.3 m32.9 m32.5 m

Total Assets

181.9 m171.3 m142.4 m

Accounts Payable

12.7 m9.8 m8.5 m

Current Liabilities

29.7 m29.9 m35.5 m

Non-Current Liabilities

117 k

Total Liabilities

29.8 m41.5 m

Additional Paid-in Capital

390.6 m410.7 m428.2 m

Retained Earnings

(238.6 m)(271.4 m)(327.4 m)

Total Equity

139.4 m100.9 m

Financial Leverage

1.2 x1.4 x
USDQ1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

76.7 m65.3 m62.2 m58.2 m79.3 m103.1 m

Accounts Receivable

26.9 m25.8 m23 m24.3 m25.4 m27.9 m

Inventories

15.4 m18.2 m18.2 m16.9 m16.2 m16.6 m

Current Assets

123.4 m112.8 m106.7 m102.1 m122.9 m151.8 m

PP&E

33.7 m33.6 m33.2 m31.8 m31.2 m30.2 m

Total Assets

162.4 m151.2 m145 m138.3 m158.7 m186.9 m

Accounts Payable

9.8 m8.3 m8.3 m8.8 m7.6 m8.8 m

Current Liabilities

29.9 m28 m35 m30.5 m32.4 m38.7 m

Additional Paid-in Capital

415.2 m421 m424.2 m432.1 m440.3 m443.4 m

Retained Earnings

(284.6 m)(299.8 m)(322.5 m)(329.3 m)(328.3 m)(330.1 m)

Total Equity

130.6 m121.3 m101.8 m102.9 m112.1 m113.5 m

Financial Leverage

1.2 x1.2 x1.4 x1.3 x1.4 x1.6 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(35.3 m)(32.8 m)(56 m)

Depreciation and Amortization

1.2 m2.2 m3.7 m

Accounts Receivable

(6.7 m)(11 m)7.3 m

Inventories

(6.6 m)(1.1 m)(3.5 m)

Accounts Payable

4.6 m581 k(970 k)

Cash From Operating Activities

58.7 m(42.8 m)(23.2 m)

Cash From Investing Activities

(13.4 m)(23 m)(3.8 m)

Cash From Financing Activities

99 m2.6 m4.1 m

Interest Paid

534 k23 k
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

(8.2 m)(13.5 m)(24.2 m)(13.3 m)(28.4 m)(51.1 m)(1.9 m)(815 k)(2.6 m)

Depreciation and Amortization

367 k751 k1.3 m887 k1.8 m2.7 m957 k1.9 m2.9 m

Accounts Receivable

(1.7 m)(5.5 m)(10.9 m)3.8 m4.9 m7.5 m(1.3 m)(2.5 m)(5.1 m)

Inventories

(1.8 m)(1.1 m)(329 k)(1.5 m)(4.3 m)(4.3 m)553 k1.3 m835 k

Accounts Payable

2.1 m467 k2.7 m(18 k)(1.1 m)(1.4 m)257 k(1 m)190 k

Cash From Operating Activities

(15.1 m)(4.8 m)(17.6 m)(20.2 m)(2.1 m)13.8 m16.5 m

Purchases of PP&E

(282 k)(481 k)(841 k)

Cash From Investing Activities

(5.2 m)(13.9 m)(19 m)(2.4 m)(3.6 m)(4.1 m)(452 k)(856 k)(1.3 m)

Cash From Financing Activities

(517 k)(246 k)934 k19 k2.7 m2.7 m84 k5.7 m27.3 m
USDY, 2017

Revenue/Employee

89.7 k

Financial Leverage

1.6 x

Cardiovascular Systems Market Value History

Traffic Overview of Cardiovascular Systems

Cardiovascular Systems Company Life and Culture

You may also be interested in